More Candidate COVID-19 Vaccines Expected To Enter WHO’s Global Trial
A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.
You may also be interested in...
EU Bodies Back Mix-And-Match Approach For COVID-19 Boosters
New advice on the use of "mix-and-match" primary and booster vaccine regimens has been published by the EMA and the ECDC, while a new CEPI-supported clinical trial will test heterologous booster combinations involving Medigen’s COVID-19 vaccine and other jabs.
Taiwan Starts Dosing Homegrown Vaccine Amid Import Challenges
Taiwan's president the first to receive domestically developed vaccine which results so far suggest has high efficacy, amid multiple challenges for the local inoculation campaign.
Arcturus Leaps On COVID-19 Trials And Investor Interest In mRNA
Singapore has granted approval for a Phase I/II trial of Arcturus’s next generation mRNA COVID-19 vaccine candidates, hot on the heels of a similar approval from Vietnam earlier this week. The biotech’s share price duly rocketed, but there may be more at play.